Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada approves BioCurex' Histo-RECAF cancer diagnostic:

This article was originally published in Clinica

Executive Summary

Canada has approved for sale BioCurex' Histo-RECAF diagnostic test kit for detecting cancers of the breast, lung, stomach, prostate and lymph node tissues. The test, which can detect malignant cancers from blood or tissue samples, is based on the identification of a common cancer biomarker, known as RECAF. The Rancho Santa Margarita, California firm says that research has shown the test to have a sensitivity of 100% in the detection of breast cancer (see Clinica No 967, p 17). It adds that it will also file for approval in other strategic markets shortly.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel